- cafead   Mar 11, 2024 at 11:42: AM
via Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of the disorder.
article source
article source